U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Glioblastoma

MedGen UID:
1788246
•Concept ID:
C5447501
•
Neoplastic Process

Definition

A glioblastoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Glioblastoma

Professional guidelines

PubMed

Treatment of unresectable glioblastoma multiforme.
Nieder C, Grosu AL, Astner S, Molls M
Anticancer Res 2005 Nov-Dec;25(6C):4605-10. PMID: 16334150

Recent clinical studies

Etiology

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M
J Neurooncol 2021 Sep;154(2):187-196. Epub 2021 Jul 28 doi: 10.1007/s11060-021-03812-9. PMID: 34322829Free PMC Article
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Lesimple T, Riffaud L, Frappaz D, Ben Hassel M, Gédouin D, Bay JO, Linassier C, Hamlat A, Piot G, Fabbro M, Saïkali S, Carsin B, Guégan Y
J Neurooncol 2009 Jun;93(2):253-60. Epub 2009 Jan 13 doi: 10.1007/s11060-008-9774-3. PMID: 19139825
Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
Kong DS, Nam DH, Lee JI, Park K, Kim JH
J Neurosurg 2006 Dec;105 Suppl:139-43. doi: 10.3171/sup.2006.105.7.139. PMID: 18503347
Treatment of unresectable glioblastoma multiforme.
Nieder C, Grosu AL, Astner S, Molls M
Anticancer Res 2005 Nov-Dec;25(6C):4605-10. PMID: 16334150
Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C
Anticancer Drugs 2003 Apr;14(4):305-12. doi: 10.1097/00001813-200304000-00008. PMID: 12679735

Diagnosis

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M
J Neurooncol 2021 Sep;154(2):187-196. Epub 2021 Jul 28 doi: 10.1007/s11060-021-03812-9. PMID: 34322829Free PMC Article
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW
J Neurol 2017 Feb;264(2):350-358. Epub 2016 Dec 5 doi: 10.1007/s00415-016-8355-1. PMID: 27921166
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ
Cancer Med 2013 Apr;2(2):185-95. Epub 2013 Jan 24 doi: 10.1002/cam4.58. PMID: 23634286Free PMC Article
Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
Kong DS, Nam DH, Lee JI, Park K, Kim JH
J Neurosurg 2006 Dec;105 Suppl:139-43. doi: 10.3171/sup.2006.105.7.139. PMID: 18503347
Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C
Anticancer Drugs 2003 Apr;14(4):305-12. doi: 10.1097/00001813-200304000-00008. PMID: 12679735

Therapy

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M
J Neurooncol 2021 Sep;154(2):187-196. Epub 2021 Jul 28 doi: 10.1007/s11060-021-03812-9. PMID: 34322829Free PMC Article
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE 2nd, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ
Cancer Med 2013 Apr;2(2):185-95. Epub 2013 Jan 24 doi: 10.1002/cam4.58. PMID: 23634286Free PMC Article
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Lesimple T, Riffaud L, Frappaz D, Ben Hassel M, Gédouin D, Bay JO, Linassier C, Hamlat A, Piot G, Fabbro M, Saïkali S, Carsin B, Guégan Y
J Neurooncol 2009 Jun;93(2):253-60. Epub 2009 Jan 13 doi: 10.1007/s11060-008-9774-3. PMID: 19139825
Treatment of unresectable glioblastoma multiforme.
Nieder C, Grosu AL, Astner S, Molls M
Anticancer Res 2005 Nov-Dec;25(6C):4605-10. PMID: 16334150
Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C
Anticancer Drugs 2003 Apr;14(4):305-12. doi: 10.1097/00001813-200304000-00008. PMID: 12679735

Prognosis

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M
J Neurooncol 2021 Sep;154(2):187-196. Epub 2021 Jul 28 doi: 10.1007/s11060-021-03812-9. PMID: 34322829Free PMC Article
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE 2nd, McSherry F, Friedman HS, Vredenburgh JJ
Oncologist 2015 Jul;20(7):727-8. Epub 2015 May 29 doi: 10.1634/theoncologist.2015-0135. PMID: 26025933Free PMC Article
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Lesimple T, Riffaud L, Frappaz D, Ben Hassel M, Gédouin D, Bay JO, Linassier C, Hamlat A, Piot G, Fabbro M, Saïkali S, Carsin B, Guégan Y
J Neurooncol 2009 Jun;93(2):253-60. Epub 2009 Jan 13 doi: 10.1007/s11060-008-9774-3. PMID: 19139825
Treatment of unresectable glioblastoma multiforme.
Nieder C, Grosu AL, Astner S, Molls M
Anticancer Res 2005 Nov-Dec;25(6C):4605-10. PMID: 16334150
Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C
Anticancer Drugs 2003 Apr;14(4):305-12. doi: 10.1097/00001813-200304000-00008. PMID: 12679735

Clinical prediction guides

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Takigawa K, Hata N, Michiwaki Y, Hiwatashi A, Yonezawa H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Funakoshi Y, Otsuji R, Sako A, Togao O, Yoshiura T, Yoshimoto K, Mizoguchi M
J Neurooncol 2021 Sep;154(2):187-196. Epub 2021 Jul 28 doi: 10.1007/s11060-021-03812-9. PMID: 34322829Free PMC Article
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW
J Neurol 2017 Feb;264(2):350-358. Epub 2016 Dec 5 doi: 10.1007/s00415-016-8355-1. PMID: 27921166
Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
Kong DS, Nam DH, Lee JI, Park K, Kim JH
J Neurosurg 2006 Dec;105 Suppl:139-43. doi: 10.3171/sup.2006.105.7.139. PMID: 18503347
Treatment of unresectable glioblastoma multiforme.
Nieder C, Grosu AL, Astner S, Molls M
Anticancer Res 2005 Nov-Dec;25(6C):4605-10. PMID: 16334150
Survival and prognostic factors of patients with unresectable glioblastoma multiforme.
Fazeny-Dörner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C
Anticancer Drugs 2003 Apr;14(4):305-12. doi: 10.1097/00001813-200304000-00008. PMID: 12679735

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...